Search

Your search keyword '"Begaud B"' showing total 230 results
Start Over Author "Begaud B"
230 results on '"Begaud B"'

5. How to Anticipate the Assessment of the Public Health Benefit of New Medicines?

Author

Alperovitch, A., Bamberger, M., Begaud, B., Blin, O., Blin, P., Breart, G., Brun Strang, C., Buyse, M., Castot, A., Chauvenet, M., Chicoye, A., David, N., De Bels, F., De Sahb Berkovitch, R., Dohin, E., Fagnani, F., Falissard, B., Gastaldi-Menager, C., Giri, I., Haim, M., Joubert, J.M., Lapeyre-Mestre, M., Lassale, C., Marchant Ramirez, I., Meyer, F., Micallef, J., Mollimard, M., Moreau-Defarges, T., Pazart, L., Perret, L., Pigeon, M., Rumeau Pichon, C., Tcheng, Ph., Woler, M., Zanetti, L., Zylberman, M., Massol, Jacques, Puech, Alain, and Boissel, Jean-Pierre

Published
2007
Full Text
View/download PDF

6. Comment anticiper l’évaluation de l’intérêt de santé publique des médicaments ?

Author

Alperovitch, A., Bamberger, M., Bégaud, B., Blin, O., Blin, P., Bréart, G., Brun Strang, C., Buyse, M., Castot, A., Chauvenet, M., Chicoye, A., David, N., De Bels, F., De Sahb Berkovitch, R., Dohin, E., Fagnani, F., Falissard, B., Gastaldi-Menager, C., Giri, I., Haim, M., Joubert, J.M., Lapeyre-Mestre, M., Lassale, C., Marchant Ramirez, I., Meyer, F., Micallef, J., Mollimard, M., Moreau-Defarges, T., Pazart, L., Perret, L., Pigeon, M., Rumeau Pichon, C., Tcheng, Ph., Woler, M., Zanetti, L., Zylberman, M., Massol, Jacques, Puech, Alain, and Boissel, Jean-Pierre

Published
2007
Full Text
View/download PDF

19. Incidence and Prevalence of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Primary Care—The Triumph Project

Author

Verhamme, Km, Dieleman, Jp, Bleumink, Gs, VAN DER LEI, J, Sturkenboom, Mc, Artibani, W, Begaud, B, Berges, R, Borkowski, A, Chappel, Cr, Costello, A, Dobronski, P, Farmer, Rd, JIMENEZ CRUZ, F, Jonas, U, Macrae, K, Pientka, L, Rutten, Ff, Van, Schayck, Cp, Speakman, Mj, Tiellac, P, Tubaro, Andrea, Vallencien, G, Vela, Navarrete, R, and TRIUMPH PAN EUROPEAN EXPERT PANEL

Subjects
Male, medicine.medical_specialty, Urology, Population, Prostatic Hyperplasia, Prevalence, urologic and male genital diseases, Cohort Studies, Age Distribution, Lower urinary tract symptoms, Internal medicine, medicine, Humans, education, Aged, Netherlands, Retrospective Studies, Aged, 80 and over, Gynecology, education.field_of_study, Primary Health Care, urogenital system, business.industry, Incidence, Incidence (epidemiology), Retrospective cohort study, Middle Aged, medicine.disease, Databases as Topic, Cohort, Population study, business, Cohort study
Abstract

Objective: Benign prostatic hyperplasia (BPH) is one of the most common conditions associated with ageing in men. BPH often presents as lower urinary tract symptoms (LUTS) due to difficulties in voiding and irritability of the bladder. We conducted a retrospective cohort study within the Integrated Primary Care Information (IPCI) database, a general practitioners database in The Netherlands, to assess the incidence of LUTS suggestive of BPH (LUTS/BPH) in the general population. Materials: Our study population comprised all males, 45 years or older who were registered for at least 6 months prior to start of follow-up. The study period lasted from 1 January 1995 to 31 December 2000. Cases of LUTS/BPH were defined as persons with a diagnosis of BPH, treatment or surgery for BPH, or urinary symptoms suggestive of BPH that could not be explained by other co-morbidity. Results: The study cohort comprised 80,774 males who contributed 141,035 person-years of follow-up. We identified 2181 incident and 5605 prevalent LUTS/BPH cases. The overall incidence rate of LUTS/BPH was 15 per 1000 man-years (95% CI: 14.8–16.1). The incidence increased linearly ( r 2 =0.99) with age from three cases per 1000 man-years at the age of 45–49 years (95% CI: 2.4–3.6) to a maximum of 38 cases per 1000 man-years at the age of 75–79 years (95% CI: 34.1–42.9). After the age of 80 years, the incidence rate remained constant. For a symptom-free man of 46 years, the risk to develop LUTS/BPH over the coming 30 years, if he survives, is 45%. The overall prevalence of LUTS/BPH was 10.3% (95% CI: 10.2–10.5). The prevalence rate was lowest among males 45–49 years of age (2.7%) and increased with age until a maximum at the age of 80 years (24%). Conclusions: The incidence rate of LUTS/BPH increases linearly with age and reaches its maximum at the age of 79 years.

Published
2002

32. Drug reimbursement: indicators of inappropriate resource allocation

Author

Begaud, B, Bergmann, U., Eichler, H.G., Leufkens, H.G.M., Meier, P.J., Population-based studies of drug treatment: from molecule to patient outcomes, Universiteit Utrecht, and Dep Farmaceutische wetenschappen

Subjects
Farmacie/Biofarmaceutische wetenschappen (FARM), Ziekenhuisstructuur en organisatie van de gezondheidszorg, Epidemiology, Farmacie(FARM), Public Health, Biomedische technologie en medicijnen
Published
2002

33. Drug reimbursement: indicators of inappropriate resource allocation

Author

Begaud, B., Ulf Bergman, Eichler, Hg, Leufkens, Hgm, Meier, Pj, Population-based studies of drug treatment: from molecule to patient outcomes, Universiteit Utrecht, and Dep Farmaceutische wetenschappen

Subjects
Farmacie/Biofarmaceutische wetenschappen (FARM), Ziekenhuisstructuur en organisatie van de gezondheidszorg, Epidemiology, Farmacie(FARM), Public Health, Biomedische technologie en medicijnen
Published
2002

34. Neuropathy associated with leflunomide: a case series

Author

Martin, K, Bentaberry, F, Dumoulin, C, Longy-Boursier, M, Lifermann, F, Haramburu, F, Dehais, J, Schaeverbeke, T, Begaud, B, and Moore, N

Subjects
Rheumatoid arthritis -- Care and treatment, Rheumatoid arthritis -- Drug therapy, Rheumatoid arthritis -- Risk factors, Peripheral nerve diseases -- Risk factors, Leflunomide -- Drug therapy, Leflunomide -- Risk factors, Health
Published
2005

40. How to Anticipate the Assessment of the Public Health Benefit of New Medicines?

Author

Massol, Jacques, primary, Puech, Alain, additional, Boissel, Jean-Pierre, additional, Alperovitch, A., additional, Bamberger, M., additional, Begaud, B., additional, Blin, O., additional, Blin, P., additional, Breart, G., additional, Brun Strang, C., additional, Buyse, M., additional, Castot, A., additional, Chauvenet, M., additional, Chicoye, A., additional, David, N., additional, De Bels, F., additional, De Sahb Berkovitch, R., additional, Dohin, E., additional, Fagnani, F., additional, Falissard, B., additional, Gastaldi-Menager, C., additional, Giri, I., additional, Haim, M., additional, Joubert, J.M., additional, Lapeyre-Mestre, M., additional, Lassale, C., additional, Marchant Ramirez, I., additional, Meyer, F., additional, Micallef, J., additional, Mollimard, M., additional, Moreau-Defarges, T., additional, Pazart, L., additional, Perret, L., additional, Pigeon, M., additional, Rumeau Pichon, C., additional, Tcheng, Ph., additional, Woler, M., additional, Zanetti, L., additional, and Zylberman, M., additional

Published
2007
Full Text
View/download PDF

50. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX- inhibiting Therapies (SELECT) trial in osteoarthritis

Author

Dequeker, J., primary, Hawkey, C., additional, Kahan, A., additional, Steinbruck, K., additional, Alegre, C., additional, Baumelou, E., additional, Begaud, B., additional, Isomaki, H., additional, Littlejohn, G., additional, Mau, J., additional, and Papazoglou, S., additional

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results